Captopril for Hypertension
Captopril is an ACE inhibitor indicated for hypertension treatment, with an initial dose of 25 mg twice or three times daily taken one hour before meals, titrated up to 50 mg two to three times daily if needed, with a maximum of 150 mg three times daily (450 mg/day total). 1
Indications
Captopril is FDA-approved for:
- Hypertension (as monotherapy or combination therapy)
- Heart failure (in combination with diuretics and digitalis)
- Left ventricular dysfunction post-MI (target dose 50 mg three times daily)
- Diabetic nephropathy (25 mg three times daily for type 1 diabetes with proteinuria >500 mg/day and retinopathy) 1
Important context: While current guidelines 2, 3 recommend ACE inhibitors as first-line agents for hypertension, they do not specifically prioritize captopril over other ACE inhibitors. Modern practice typically favors longer-acting ACE inhibitors (like enalapril, lisinopril) due to once-daily dosing and better adherence. However, captopril remains a valid option with proven efficacy.
Dosing Regimen
For Hypertension:
Standard approach:
- Initial: 25 mg twice or three times daily
- Titration: If BP not controlled after 1-2 weeks, increase to 50 mg twice or three times daily
- Maximum monotherapy: Usually 50 mg three times daily (150 mg/day)
- With diuretic: If still uncontrolled, add hydrochlorothiazide 25 mg daily
- Absolute maximum: 150 mg three times daily (450 mg/day) 1
Critical timing: Must be taken one hour before meals for optimal absorption 1
Special Situations:
Patients already on diuretics (high risk for first-dose hypotension):
- Start with 6.25-12.5 mg three times daily under close supervision
- Titrate gradually over several days 1, 4
Severe/malignant hypertension:
- Start 25 mg twice or three times daily under continuous medical supervision
- Can increase every 24 hours if needed
- Continue diuretic but stop other antihypertensives 1
Heart failure:
- Start 6.25-12.5 mg three times daily if volume depleted
- Otherwise 25 mg three times daily
- Target 50-100 mg three times daily 1
Monitoring Parameters
Before initiation:
- Baseline blood pressure (including orthostatic measurements)
- Renal function (creatinine, eGFR)
- Serum potassium
- Complete blood count (CBC) - especially important given neutropenia/agranulocytosis risk
- Screen for volume depletion/hyponatremia if on diuretics
During treatment:
- Blood pressure: Monitor closely during titration, especially first dose if on diuretics
- Renal function: Check within 1-2 weeks of initiation and dose changes, then periodically
- Potassium: Monitor regularly (risk of hyperkalemia)
- CBC: Particularly in patients with renal impairment or collagen vascular disease (risk of neutropenia/agranulocytosis) 1
- Proteinuria: Baseline and periodic monitoring
Common pitfall: The FDA label 1 emphasizes close medical supervision when starting captopril in patients already on diuretics due to significant first-dose hypotension risk.
Contraindications
Absolute contraindications:
- History of angioedema with ACE inhibitors
- Pregnancy (all trimesters)
- Bilateral renal artery stenosis or stenosis in a solitary kidney
- Concomitant use with aliskiren in diabetic patients
Relative contraindications/high-risk situations:
- Collagen vascular disease (especially with renal impairment) - reserve captopril for treatment failures due to neutropenia/agranulocytosis risk 1
- Severe renal impairment - requires dose adjustment
- Volume depletion/hyponatremia - correct before initiating
- Aortic stenosis - use with caution
Key Clinical Considerations
Black patients: ACE inhibitors may be less effective as monotherapy in Black patients; combination with a diuretic or calcium channel blocker is often needed 3, 1
Elderly patients: Equally effective but start with lower doses if volume depleted 5
Combination therapy: Current guidelines 3 recommend combination therapy as initial treatment for most patients with confirmed hypertension (BP ≥140/90 mmHg). Preferred combinations are ACE inhibitor + calcium channel blocker or diuretic. Never combine two RAS blockers (ACE inhibitor + ARB) 3
Adverse effects to monitor:
- Dry cough (class effect)
- Dysgeusia (taste disturbance - more common with captopril than other ACE inhibitors)
- Hyperkalemia
- Acute kidney injury (especially with volume depletion)
- Angioedema (higher risk in Black patients) 1
- Neutropenia/agranulocytosis (rare but serious, especially with renal impairment or collagen vascular disease) 1, 6
Modern context: While captopril is effective 5, 6, 7, its three-times-daily dosing and need for pre-meal administration limit adherence compared to once-daily ACE inhibitors. Consider longer-acting alternatives unless there's a specific reason to use captopril (e.g., need for rapid titration, cost considerations).